Free Trial
NASDAQ:CBUS

Cibus (CBUS) Stock Price, News & Analysis

Cibus logo
$3.97 -0.37 (-8.53%)
(As of 11/20/2024 ET)

About Cibus Stock (NASDAQ:CBUS)

Key Stats

Today's Range
$3.94
$4.40
50-Day Range
$2.94
$5.75
52-Week Range
$2.86
$23.18
Volume
143,603 shs
Average Volume
147,703 shs
Market Capitalization
$105.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.83
Consensus Rating
Buy

Company Overview

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Cibus Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

CBUS MarketRank™: 

Cibus scored higher than 56% of companies evaluated by MarketBeat, and ranked 84th out of 139 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cibus has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cibus has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cibus' stock forecast and price target.
  • Earnings Growth

    Earnings for Cibus are expected to grow in the coming year, from ($3.50) to ($2.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cibus is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cibus is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cibus has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cibus' valuation and earnings.
  • Percentage of Shares Shorted

    10.00% of the float of Cibus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cibus has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

  • Dividend Yield

    Cibus does not currently pay a dividend.

  • Dividend Growth

    Cibus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.00% of the float of Cibus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cibus has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

  • News Sentiment

    Cibus has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Cibus this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for CBUS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    6 people have added Cibus to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cibus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,839.00 in company stock.

  • Percentage Held by Insiders

    49.40% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 33.81% of the stock of Cibus is held by institutions.

  • Read more about Cibus' insider trading history.
Receive CBUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cibus and its competitors with MarketBeat's FREE daily newsletter.

CBUS Stock News Headlines

Cibus, Inc. (NASDAQ:CBUS) CFO Sells $24,629.10 in Stock
Cibus, Biographica enter collaboration using AI to advance canola, oilseed rape
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
Cibus Enhances Board with Appointment of August Moretti
Cibus to Participate in the 13th Annual Roth Technology Conference
HC Wainwright Issues Pessimistic Outlook for Cibus Earnings
Cibus completed edits in Canola for 4th mode of action
See More Headlines

CBUS Stock Analysis - Frequently Asked Questions

Cibus' stock was trading at $19.64 on January 1st, 2024. Since then, CBUS shares have decreased by 79.8% and is now trading at $3.97.
View the best growth stocks for 2024 here
.

Cibus, Inc. (NASDAQ:CBUS) posted its earnings results on Thursday, August, 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.33. The business earned $0.84 million during the quarter, compared to analysts' expectations of $0.44 million. Cibus had a negative net margin of 10,724.78% and a negative trailing twelve-month return on equity of 28.17%.

Cibus (CBUS) raised $100 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO.

Cibus' top institutional shareholders include FMR LLC (14.79%), Geode Capital Management LLC (1.38%), State Street Corp (1.16%) and Charles Schwab Investment Management Inc. (0.21%). Insiders that own company stock include Gregory Francis William Gocal, Gerhard Prante and Carlo Broos.
View institutional ownership trends
.

Shares of CBUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cibus investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V), Netflix (nflx) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/08/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/20/2025

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
Chemicals
Current Symbol
NASDAQ:CBUS
Fax
N/A
Employees
183
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.83
High Stock Price Target
$25.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+475.1%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-267,640,000.00
Net Margins
-10,724.78%
Pretax Margin
-12,860.54%

Debt

Sales & Book Value

Annual Sales
$1.82 million
Cash Flow
$6.73 per share
Book Value
$12.38 per share

Miscellaneous

Free Float
13,387,000
Market Cap
$105.05 million
Optionable
Optionable
Beta
1.79
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:CBUS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners